Wedbush Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $122

Benzinga · 1d ago
Wedbush analyst Laura Chico maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and raises the price target from $105 to $122.